The development of effective antimicrobial agents and vaccines has transformed societal expectations by reducing the frequency of some events (e.g. childhood deaths from bacterial meningitis) to vanishingly low levels in the developed world. However, the need for further advances in this area has arguably never been greater: antimicrobial resistance has reduced the utility of many existing agents, new pathogens continue to emerge or at least to be recognized, including the ever-present threat of pandemic influenza, and economic realities have altered the risk-benefit-value equation for all concerned parties. In this context, an issue of Current Opinion in Infectious Diseases that focuses on approaches to these problems is timely.

On the bacterial front, Balagopal and Sears review new approaches to *Clostridium difficile*-associated diarrhea (CDAD), an entity that has appeared in a more aggressive and widespread form over the past several years. Although vancomycin and metronidazole remain the mainstays of therapy at present, work with nitazoxanide, tolevamer, rifaximin, and ramoplanin suggests that new options may be forthcoming. Taking on an even more vexing clinical challenge, Dr Bonomo examines the rapidly spreading problem of extended-spectrum beta-lactamases (ESBLs). As there are very few projects currently known in the pipeline for difficult-to-treat Gram-negative infections, the possibility that beta-lactams might be reinvigorated by means of novel beta lactamase-inhibitor combinations is exciting. However, the rapidly expanding spectrum of the ESBLs makes identification of suitably broad-spectrum inhibitors very challenging.

Turning towards the viral front, both progress and challenges are examined. Dr Bonnez provides a review of the very exciting progress made in developing vaccines that prevent genital HPV infection and thus may reduce risk of prevent cervical cancer. Based on the key principle that non-infectious but immunogenic virus-like particles elicit production of neutralizing antibodies, the recent licensure of two vaccines appears poised to delivery a step-change in health care. Dr Kahn surveys the narrowing gap between known and unknown causes of acute respiratory illness and thus highlights the potential for discovering new pathogens. Recent work has now provided identification of multiple new human respiratory viruses, including human metapneumovirus, human bocavirus, and human coronaviruses NL63 and HKU1. Finally, Drs Keitel and Atmar review the vaccine work ongoing to prepare for the potential threat of pandemic emergence of H5N1 influenza virus. Although we hope to never see such an event, the preparation activities are yielding many insights and advances that can be used to improve our approaches to managing interpandemic influenza or a pandemic due to another influenza virus.

Completing the survey, two papers examine themes that are relevant to all antimicrobial agents. Using pharmacokinetics and pharmacodynamics to optimise antimicrobial usage is rapidly becoming standard practice. In this light, Dr Lewis provides a specific review of the optimal use of the antifungal agents. Of interest, unconventional dosing strategies may have utility in selected patient settings. Going one step further, Dr Theuretzbacher shows that work with these concepts is based on our understanding of plasma concentrations even though tissue concentrations may be more relevant. Knowledge of tissue concentrations may also be used in selected settings to help reduced the likelihood of development of resistance.

We thank the contributors to this issue. Optimal discovery, development, and use of antimicrobial agents will definitely remain a significant challenge that requires the type of broad-based and rigorous thinking exemplified by their reviews.
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